Thirty years have passed since missense mutations in RAS were fi rst identifi ed as the transforming factors in the Harvey and Kirsten strains of the mouse sarcoma virus. Somatic mutations of the 3 RAS genes have since been shown to be among the most prevalent somatic alterations in human cancer. Studies using genetically engineered mouse models (GEMM) of pancreatic and lung cancer, among others, have confi rmed that mutant RAS contributes to cancer initiation and maintenance of the transformed phenotype even in the setting of established, metastatic disease. These results have prompted intensive academic-and industry-led efforts to identify direct inhibitors of oncogenic RAS. These efforts have failed to date likely due to the high affi nity of the RAS-GTP interaction, as have efforts to selectively inhibit the posttranslational modifi cations required for RAS activation. The latter approach was ineffective in KRAS-and NRAS-mutant tumors as geranylgeranyl modifi cation can substitute for farnesylation in targeting KRAS and NRAS to the plasma membrane.
tional events. In this issue of Cancer Discovery, Collisson and colleagues (1) set out to investigate which of the various RAS effectors are required for tumor initiation and progression in pancreatic ductal adenocarcinoma (PDA). An in-depth focus on PDA is justifi ed by the high rate of KRAS mutation in this disease (>90%) and the urgent need to develop effective therapies for this common and almost universally lethal cancer.
Prior studies using GEMMs have shown that expression of mutant Kras leads to the formation of multifocal pancreatic intraepithelial neoplasms (PanIN; ref. 2) . Furthermore, coincident loss of Ink4a/Arf or Trp53 function results in the development of invasive pancreatic adenocarcinomas that phenocopy the human disease (3, 4) . To determine whether RAF activation is suffi cient to initiate pancreatic tumor formation, the authors generated mice with constitutive or conditional expression of Braf V600E in pancreatic cells. The V600E mutation accounts for more than 90% of the BRAF mutations found in human tumors and locks the kinase into a constitutively active conformation. In the Braf CA mouse model generated by Dankort and colleagues (5), the Braf CA allele contains an insert that includes a fl oxed cassette containing exons 15 to 18 of human wildtype Braf cDNA upstream of a modified exon 15, which harbors the V600E mutation. The wild-type Braf allele is expressed before Cre-mediated recombination, but upon expression of Cre, the wild-type exon 15 to 18 insert is excised, and the expression of Braf V600E is initiated under the control of the endogenous Braf promoter. Targeted expression of Braf V600E using this model in the mouse lung leads to the development of benign lung tumors that progress to adenocarcinoma in the setting of concomitant loss of Trp53 or Ink4A/Arf (5) . Similarly, conditional melanocyte-specific expression of Braf V600E in mice using this model results in benign melanocytic hyperplasia, which in the setting of coincident Pten loss progresses to invasive melanoma (6) .
In the current study, Collisson and colleagues (1) ) had no apparent phenotype. These results suggest that RAF but not PI3K activation is suffi cient to induce PanIN development. Limitations of this study include the possibility that oncogenic RAS does not exclusively activate p110α PI3K, and that the spectrum of downstream effectors activated by the kinase domain mutant may differ from that regulated by an activated wild-type allele. Furthermore, in light of recent fi ndings that the class IB PI3K p110γ isoform is overexpressed in PDA (7) and that deletion of Pten in mouse pancreatic centroacinar cells leads to ductal malignancy (8), the current data do not fully exclude the possibility that activation of PI3K signaling by other mechanisms may be suffi cient to induce PanIN formation.
Overall, the results imply that inhibition of RAF signaling may be an effective therapeutic approach in patients with KRAS-mutant pancreatic tumors (Fig. 1) . Highly selective RAF inhibitors were recently shown to prolong the survival of patients with BRAF V600E melanoma. These agents, however, inhibit RAF activation in a mutant-selective manner and are thus ineffective in tumors that express activated RAS (9) . Highly selective, allosteric inhibitors of mitogenactivated protein (MAP)/ERK kinase (MEK) have also shown promising activity in BRAF-mutant melanoma and provide an alternative approach to inhibiting ERK pathway activity in KRAS-mutant tumors (10). To dete rmine whether MEK inhibitors could inhibit ERK signaling at a nontoxic dose, Collisson and colleagues (1) treated Kras LSL-G12D ; Trp53 LSL-R270H/+ ; p48 Cre mice with PD0325901, an allosteric inhibitor of MEK1 and MEK2. Treatment with PD032901 potently downregulated ERK activity, as measured by a decrease in phosphorylated ERK expression, indicating that suffi cient intratumoral levels of the MEK inhibitor could be achieved at nontoxic doses to potently inhibit ERK pathway activation. This result is notable, as resistance of pancreatic tumors to systemic cytotoxic therapies has been attributed to limited drug exposure resulting from poor intratumoral perfusion. To determine whether suffi cient ERK pathway inhibition could be maintained to induce meaningful antitumor effects, the authors turned to an orthotopic, syngeneic model of PDA. In this model, treatment with the MEK inhibitor was associated with downregulation of phosphorylated ERK expression and an improvement in survival. In sum, the results provide strong rationale for clinical trials of MEK inhibitors in patients with advanced pancreatic cancer but also highlight the logistical challenges associated with the use of GEMMs for preclinical drug development.
Recently, the MEK inhibitor trametinib (GSK1120212) was shown to improve survival as compared with chemotherapy in a randomized trial of patients with metastatic melanoma whose tumors harbored BRAF V600E/K mutations (10) . On the basis of these results, U.S. Food and Drug Administration approval for the use of trametinib in patients with BRAF-mutant melanoma is anticipated. Notably, 22 patients with pancreatic cancer were treated with trametinib within the context of the phase I trial of this agent (11) . One patient achieved a partial response and several additional patients were noted to have minor responses or stable disease. Although these results are disappointing in light of the GEMM studies reported by Collisson and colleagues (1), they are consistent with studies of human cancer cell lines conducted by this group and others showing that in contrast to BRAF-mutant cell lines, which are with rare exception sensitive to MEK inhibition, KRAS-mutant cell lines exhibit variable sensitivity to MEK inhibitors. The basis for this heterogeneity of MEK dependence in KRAS-mutant cell lines has been explored in colorectal cancer cell lines and in this context can be attributed, in part, to the presence of PIK3CA co-mutation in some models (12) . While PIK3CA mutations are rarely observed in pancreatic cancers, Collisson and colleagues (1) show that MEK inhibition in KRAS-mutant PDA cell lines is associated with a reciprocal increase in the expression of phosphorylated AKT and that cotreatment with a selective inhibitor of AKT is associated with synergy in many, but not all, models.
In sum, the results reported by Collisson and colleagues (1) in concert with the clinical experience to date indicate that despite the suffi ciency of RAF activation for PanIN development, MEK inhibitor-based combination approaches will be needed to induce durable tumor regressions in most patients with KRAS-mutant PDA. Future laboratory studies will be needed to defi ne the molecular basis for the variable response of KRAS-mutant PDA tumors to MEK inhibition, as such studies would aid in the development of rational MEK inhibitor-based combination strategies. 
